NL-OMON25937尚未招募不适用
A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction andconsolidation for patients with progressive or refractory Multiple Myeloma.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •The subject must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.
- •- Age ≥ 18 years at the time of signing the informed consent form.
排除标准
- •- Prior resistance/refractory disease to bortezomib
- •- Systemic AL amyloidosis
研究者
相似试验
招募中
2 期
A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma.10018865Multiple MyelomaNL-OMON44193Erasmus MC, Universitair Medisch Centrum Rotterdam49
进行中（未招募）
1 期
A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma.A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma.EUCTR2014-002444-40-NLErasmus MC37
进行中（未招募）
1 期
Selinexor in patients with advanced thymoma and thymic carcinomaadvanced thymic epithelial tumour (TET) progressing after primary chemotherapyMedDRA version: 21.1Level: PTClassification code 10055108Term: Thymic cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10043670Term: ThymomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10043674Term: Thymoma malignant recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061031Term: Thymoma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002612-40-DKDepartment of Oncology Rigshospitalet50
进行中（未招募）
1 期
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Relapsed/Refractory DLBCLMedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851EUCTR2014-001977-15-GRKaryopharm Therapeutics, Inc.110
进行中（未招募）
1 期
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients withRelapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Relapsed/Refractory DLBCLMedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851EUCTR2014-001977-15-BEKaryopharm Therapeutics, Inc.320